×
0 0 0 0 0 0 0 0
Stockreport

REGENXBIO receives Fast Track designation for RGX-111 gene therapy for the treatment of MPS I [Seeking Alpha]

REGENXBIO INC COMMON (RGNX)  More Company Research Source: Seeking Alpha
Last regenxbio inc common earnings: 8/8 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.regenxbio.com
PDF REGENXBIO receives Fast Track designation for RGX-111 gene therapy for the treatment of MPS IFDAgrants Fast Track designation for REGENXBIO's (NASDAQ:RGNX) RGX-111. RGX-111 is a novel, one-time investigational treatment for Mucopolysaccharidosis Type I ((MPS I)), that is designed to deliver the human iduronidase gene directly to the central nervous system using the NAV AAV9 vector.Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.Click to subscribe to real-time analytics on RGNXNow read:Protalix BioTherapeutics: What The Latest Data For OPRX-106 Foretells » [Read more]

IMPACT SNAPSHOT EVENT TIME: RGNX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
RGNX alerts
from News Quantified
Opt-in for
RGNX alerts

from News Quantified
Opt-in for
RGNX alerts

from News Quantified